

(43) International Publication Date
24 April 2014 (24.04.2014)(10) International Publication Number
WO 2014/062667 A1

(51) International Patent Classification:

C07D 401/14 (2006.01) C07D 413/06 (2006.01)
C07D 413/14 (2006.01) C07D 417/14 (2006.01)
C07D 401/06 (2006.01) A61K 31/4709 (2006.01)
C07D 409/14 (2006.01) A61P 29/00 (2006.01)

(21) International Application Number:

PCT/US2013/065026

(22) International Filing Date:

15 October 2013 (15.10.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/714,433 16 October 2012 (16.10.2012) US
61/725,537 13 November 2012 (13.11.2012) US

(71) Applicant: JANSSEN PHARMACEUTICA NV
[BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventor; and

(71) Applicant : LEONARD, Kristi A. [US/US]; 108 Manor
Drive, Lansdale, Pennsylvania 19446 (US).

(72) Inventors: BARBAY, Kent; 6311 Sunnybrook Road,
Flourtown, Pennsylvania 19031 (US). EDWARDS, James
P.; 8723 Hesby Court, San Diego, California 92129 (US).
KREUTTER, Kevin D.; 71 Thoreau Drive, Plainsboro,
New Jersey 08536 (US). KUMMER, David A.; 11945
Tivoli Park Row Unit #1, San Diego, California 92128
(US). MAHAROOOF, Umar; 128 Sunrise Drive, North
Wales, Pennsylvania 19454 (US). NISHIMURA, Rachel;
3957 30th Street, Unit 406, San Diego, California 92104
(US). URBANSKI, Maud; 14 McPherson Drive, Fleming-
ton, New Jersey 08822 (US). VENKATESAN, Harihar-
an; 17065 Bernardo Oaks Drive, San Diego, California
92128 (US). WANG, Aihua; 1723 Foxwood Drive, Jamis-
on, Pennsylvania 18929 (US). WOLIN, Ronald L.; 16309
Los Rosales Street, San Diego, California 92127 (US).

WOODS, Craig R.; 6275 Lakewood Street, San Diego,
California 92122 (US). FOURIE, Anne; 13060 Callcott
Way, San Diego, California 92130 (US). XUE, Xiaohua;
3210 Merryfield Row, San Diego, California 92121 (US).
MIRZADEGAN, Taraneh; 13367 Wyngate Pt., San
Diego, California 92130 (US). GANAMET, Kelly Lynn;
6115 Gabrielle Avenue, Ann Arbor, Michigan 48103 (US).

(74) Agents: JOHNSON, Philip S. et al.; Johnson & Johnson,
One Johnson & Johnson Plaza, New Brunswick, New Jer-
sey 08933 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

[Continued on next page]

(54) Title: PHENYL LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T



(I)

(57) Abstract: The present invention comprises compounds of Formula (I), wherein: R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, and R⁹ are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR γ t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.



Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*